CC-486, a hypomethylating agent and an oral formulation of azacitidine, demonstrated clinically significant benefits in older patients with acute myeloid leukaemia (AML) in first remission following intensive chemotherapy with or without consolidation, highlighting its potential as a new therapeutic standard in this setting, according to the results of the QUAZAR AML-001 maintenance trial presented at ASH 2019.
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves response rates and depth of response in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT), according to updated results of the phase II GRIFFIN* study presented at ASH 2019.
Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.
Luspatercept promotes red blood cell (RBC) transfusion independence among low-risk myelodysplastic syndrome (MDS) patients, according to a longer-term analysis of the MEDALIST study presented at the recently concluded 61st Annual Meeting and Exposition of the American Society of Hematology (ASH 2019).
In the treatment of stem cell transplant-ineligible patients with newly diagnosed multiple myeloma (MM), the addition of clarithromycin to lenalidomide and dexamethasone yields marked improvements in response rates that, however, do not equate to better survival, as shown in the results of the phase III GEM-Claridex trial.
Debulking tumour with two cycles of obinutuzumab prior to initiating frontline venetoclax therapy is effective for patients with absolute lymphocyte count (ALC) >25 × 109/L and lymph nodes <5 cm, with a success rate of >98 percent, and the addition of bendamustine to this therapy improves debulking for those with nodes 5–10 cm, according to a study presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH 2019).
Subcutaneous (SC) daratumumab (DARA) showed comparable performance to intravenous (IV) admission in patients with relapsed or refractory multiple myeloma (RRMM), according to a phase III, randomized, open-label, active-controlled multicentre study presented at the recently concluded 61st Annual Meeting and Exposition of the American Society of Haematology (ASH 2019).
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Ravulizumab is a potential treatment for paroxysmal nocturnal haemoglobinuria (PNH), with an efficacy and safety profile that persists over 52 weeks of follow-up, according to a new study presented at the recently concluded 61st Annual Meeting and Exposition of the American Society of Haematology (ASH 2019).
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.